Skip to Content

Elan Names Two New Directors, Says Cooke Retires

From Associated Press (September 15, 2011)

NEW YORK -- Drugmaker Elan Corp. PLC said Thursday it named Andrew von Eschenbach and Hans Peter Hasler to its board of directors, while former Elan executive Shane Cooke retired from the board.

The Irish company said Eschenbach, 69, is the president of consulting firm Samaritan Health Initiatives, and he was commissioner of the Food and Drug Administration from 2005 to 2009. Hasler, 55, is the chairman of HMB Bioventures AG and principal of HPH Management GmbH, and he was chief operating officer of Biogen Idec Inc.

Elan and Biogen are partners on the drug Tysabri, which is used as a treatment for multiple sclerosis and Crohn's disease.

Cooke was chief financial officer from July 2001 to May 2011, and had been a director since 2005. The board now has 13 members, including Chairman Robert Ingram and CEO Kelly Martin.

Shares of Elan rose 6 cents to $9.84 in afternoon trading.


Posted: September 2011